Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.

Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T.

Breast Cancer Res Treat. 2013 Jan;137(2):407-16. doi: 10.1007/s10549-012-2356-2. Epub 2012 Dec 16.

PMID:
23242614
2.

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.

Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A.

PLoS One. 2011;6(12):e28403. doi: 10.1371/journal.pone.0028403. Epub 2011 Dec 29.

3.

A clinically relevant gene signature in triple negative and basal-like breast cancer.

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M.

Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035.

4.

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M.

Eur J Cancer. 2012 Jan;48(1):12-23. doi: 10.1016/j.ejca.2011.06.025. Epub 2011 Jul 7.

PMID:
21741824
5.

Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.

Ruckhäberle E, Karn T, Engels K, Turley H, Hanker L, Müller V, Schmidt M, Ahr A, Gaetje R, Holtrich U, Kaufmann M, Rody A.

Eur J Cancer. 2010 Feb;46(3):549-57. doi: 10.1016/j.ejca.2009.11.020. Epub 2009 Dec 18.

PMID:
20022486
6.

Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer.

Karn T, Metzler D, Ruckhäberle E, Hanker L, Gätje R, Solbach C, Ahr A, Schmidt M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2010 Apr;120(3):567-79. doi: 10.1007/s10549-009-0416-z. Epub 2009 May 20.

PMID:
19455418
7.

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.

Breast Cancer Res. 2009;11(2):R15. doi: 10.1186/bcr2234. Epub 2009 Mar 9.

8.

Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis.

Rody A, Karn T, Ruckhäberle E, Hanker L, Metzler D, Müller V, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M.

Eur J Cancer. 2009 Feb;45(3):405-13. doi: 10.1016/j.ejca.2008.10.016. Epub 2008 Dec 4.

PMID:
19054665
9.

Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.

Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M.

Breast Cancer Res Treat. 2009 Feb;113(3):457-66. doi: 10.1007/s10549-008-9964-x. Epub 2008 Mar 14.

PMID:
18340528
10.

Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1.

Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, Diallo-Danebrock R, Ruckhäberle E, Metzler D, Ahr A, Solbach C, Karn T, Kaufmann M.

Clin Cancer Res. 2007 Feb 15;13(4):1115-22.

11.

Prenatal ultrasound assessment and fetal heart monitoring: analysis of dizygotic twins discordant for body stalk anomaly in the third trimester of pregnancy.

Hrgovic Z, Andonotopo W, Klobucar A, Hrgovic I, Miskovic B, Ahr A.

Ultraschall Med. 2007 Jun;28(3):321-4. Epub 2007 Feb 21.

PMID:
17315112
12.

[Risk factors for recurrence of vulvar intraepithelial neoplasia III (VIN III)].

Ahr A, Rody A, Kissler S, Kaufmann M, Gätje R.

Zentralbl Gynakol. 2006 Dec;128(6):347-51. German.

PMID:
17213974
13.

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.

Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M.

Breast. 2007 Feb;16(1):86-93. Epub 2006 Sep 28.

PMID:
17010609
14.

[Cervical cancer screening of HIV-positive women: is a prolongation of the screening interval meaningful?].

Ahr A, Rody A, Cimposiau C, Faul-Burbes C, Kissler S, Kaufmann M, Gätje R.

Zentralbl Gynakol. 2006 Oct;128(5):242-5. German.

PMID:
17001558
15.

[Management of abnormal uterine bleeding].

Gaetje R, Scharl A, Kaufmann M, Ahr A.

Zentralbl Gynakol. 2006 Aug;128(4):196-201. German.

PMID:
16835813
16.

[Identification of preeclampsia by cDNA-gene expression profiling in human placentas and serum -- a pilot study].

Ahr A, Holtrich U, Karn T, Reitter A, Rody A, Kaufmann M, Gätje R.

Zentralbl Gynakol. 2006 Jun;128(3):138-42. German.

PMID:
16758380
17.

[Integrin expression in eutopic and ectopic endometrium].

Gaetje R, Rody A, Kissler S, Kaufmann M, Ahr A.

Zentralbl Gynakol. 2006 Jun;128(3):135-7. German.

PMID:
16758379
18.
19.

Outcome of preterm and term neonates of mothers with malignant diseases diagnosed during pregnancy.

Fischer D, Ahr A, Schaefer B, Veldman A, Schloesser R.

J Matern Fetal Neonatal Med. 2006 Feb;19(2):101-3.

PMID:
16581605
20.

[Management of HIV-positive pregnancies -- results from a retrospective study].

Ahr A, Faul-Burbes C, Haardt N, Linde R, Haberl A, Bremerich D, Kissler S, Schloesser R, Kaufmann M.

Zentralbl Gynakol. 2005 Aug;127(4):242-7. German.

PMID:
16037906
21.

Predictive value of impaired uterine transport function assessed by negative hysterosalpingoscintigraphy (HSSG).

Kissler S, Wildt L, Schmiedehausen K, Kohl J, Mueller A, Rody A, Ahr A, Kuwert T, Kaufmann M, Siebzehnruebl E.

Eur J Obstet Gynecol Reprod Biol. 2004 Apr 15;113(2):204-8.

PMID:
15063961
22.

Uterine contractility and directed sperm transport assessed by hysterosalpingoscintigraphy (HSSG) and intrauterine pressure (IUP) measurement.

Kissler S, Siebzehnruebl E, Kohl J, Mueller A, Hamscho N, Gaetje R, Ahr A, Rody A, Kaufmann M.

Acta Obstet Gynecol Scand. 2004 Apr;83(4):369-74.

PMID:
15005785
23.

Mepivacaine for spinal anesthesia in parturients undergoing elective cesarean delivery: maternal and neonatal plasma concentrations and neonatal outcome.

Bremerich DH, Schlösser RL, L'Allemand N, Brandes RP, Ahr A, Piorko D, Kaufmann M, Kessler P.

Zentralbl Gynakol. 2003 Dec;125(12):518-21.

PMID:
14755363
24.

[Anesthetic regimen for HIV positive parturients undergoing elective cesarean section].

Bremerich DH, Ahr A, Büchner S, Hingott H, Kaufmann M, Faul-Burbes C, Kessler P.

Anaesthesist. 2003 Dec;52(12):1124-31. German.

PMID:
14691624
25.

Acute ethanol intoxication during pregnancy and consecutive fetal cardiac arrest: a case report.

Fischer D, Solbach C, Kitz R, Ahr A, Veldman A.

J Perinat Med. 2003;31(4):343-4.

PMID:
12951893
26.

From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression.

Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42. Epub 2003 Jun 13.

27.

[Disturbed utero-tubal transport in hysterosalpingoscintigraphy as a predictive functional test for IVF therapy].

Kissler S, Wildt L, Kohl J, Ahr A, Kaufmann M, Siebzehnrübl E.

Zentralbl Gynakol. 2002 Aug-Sep;124(8-9):418-22. German.

PMID:
12655471
28.

Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer.

Solbach C, Roller M, Ahr A, Loibl S, Nicoletti M, Stegmueller M, Kreysch HG, Knecht R, Kaufmann M.

Int J Cancer. 2002 Oct 1;101(4):390-4.

29.

Ovarian cancer antigen CA 125 influences adhesion of human and mammalian cell lines in vitro.

Gaetje R, Winnekendonk DW, Ahr A, Kaufmann M.

Clin Exp Obstet Gynecol. 2002;29(1):34-6.

PMID:
12013089
30.

[Isolated decrease of haptoglobin during pregnancy: diagnosis by chance or pathological? ].

Gatzka C, Bremerich D, Kaufmann M, Ahr A.

Zentralbl Gynakol. 2002 Feb;124(2):120-2. German.

PMID:
11935498
31.

Identification of high risk breast-cancer patients by gene expression profiling.

Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M.

Lancet. 2002 Jan 12;359(9301):131-2.

PMID:
11809257
32.

Molecular classification of breast cancer patients by gene expression profiling.

Ahr A, Holtrich U, Solbach C, Scharl A, Strebhardt K, Karn T, Kaufmann M.

J Pathol. 2001 Oct;195(3):312-20.

PMID:
11673828
33.

[Amniotic fluid embolism as an obstetric emergency--description of the syndrome and a case with fatal outcome].

Gürke B, Bremerich DH, Engels K, Ahr A, Kaufmann M.

Anasthesiol Intensivmed Notfallmed Schmerzther. 2001 Apr;36(4):247-9. German.

PMID:
11386095
34.

Cervical intraepithelial neoplasia in human immunodeficiency virus-positive patients.

Ahr A, Scharl A, Lütke K, Staszewski S, Kacer PZ, Kaufmann M.

Cancer Detect Prev. 2000;24(2):179-85.

PMID:
10917140
35.

Expression of p16 and lack of pRB in primary small cell lung cancer.

Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, Strebhardt K.

J Pathol. 1999 Nov;189(3):358-62.

PMID:
10547597
36.

Cross-reactive staining of normal bone-marrow cells by monoclonal antibody 2E11.

Ahr A, Scharl A, Müller M, von Minckwitz G, Gätje R, Pantel K, Kaufmann M.

Int J Cancer. 1999 Oct 22;84(5):502-5.

37.
38.

Cytology of ascitic fluid in a patient with metastasizing malignant Brenner tumor of the ovary. A case report.

Ahr A, Arnold G, Göhring UJ, Costa S, Scharl A, Gauwerky JF.

Acta Cytol. 1997 Jul-Aug;41(4 Suppl):1299-304.

PMID:
9990262
39.

[Blind prophylactic antibiotic administration in premature rupture of fetal membranes].

Ahr A, Scharl A, Göhring UJ, Neuhaus W, Kaufmann M.

Zentralbl Gynakol. 1997;119(3):111-6. German.

PMID:
9173768
41.

Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.

Göhring UJ, Scharl A, Thelen U, Ahr A, Crombach G.

Anticancer Res. 1996 Mar-Apr;16(2):1011-8.

PMID:
8687092
42.

Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods.

Göhring UJ, Scharl A, Thelen U, Ahr A, Crombach G, Titius BR.

J Clin Pathol. 1996 Jan;49(1):57-64.

43.

[Prognostic value of immunohistochemical determination of urokinase plasminogen activator in primary breast cancers].

Göhring UJ, Scharl A, Thelen U, Ahr A, Titius BR.

Pathologe. 1995 Nov;16(6):398-403. German.

PMID:
8570558
44.

Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.

Göhring UJ, Ahr A, Scharl A, Weisner V, Neuhaus W, Crombach G, Holt JA.

J Soc Gynecol Investig. 1995 Jul-Aug;2(4):653-9.

PMID:
9420872
45.
46.

P53 protein in 204 patients with primary breast carcinoma--immunohistochemical detection and clinical value as a prognostic factor.

Göhring UJ, Scharl A, Heckel C, Ahr A, Crombach G.

Arch Gynecol Obstet. 1995;256(3):139-46.

PMID:
7574906
47.

[Psychological disease adjustment in breast cancer patients].

Neuhaus W, Lanij B, Ahr A, Bolte A.

Geburtshilfe Frauenheilkd. 1994 Oct;54(10):564-8. German.

PMID:
8001753
48.

[Premature rupture of fetal membranes: problems and obstetric management].

Neuhaus W, Eibach HW, Ahr A, Bolte A.

Geburtshilfe Frauenheilkd. 1993 Dec;53(12):843-8. German.

PMID:
8119565

Supplemental Content

Support Center